Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)

Name: Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
Published: 2023
License: Public Domain

Hospital General Universitario Gregorio Marañon · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

ards immunotherapy systemic-inflammatory-response-syndrome

systemic inflammatory response syndrome, immune hyperactivation, regulatory t cell, ards, covid-19, advanced therapy, immunotherapy, th1-th2 balance, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)

Related documents